EXTEND II: An Open-Label Phase III Multicentre Study to Evaluate Efficacy and Safety of Ranibizumab in Chinese Patients with Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration

[1]  P. Kaiser,et al.  Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month results of the DENALI study. , 2012, Ophthalmology.

[2]  F. Lee,et al.  EXTEND III: Efficacy and safety of ranibizumab in South Korean and Taiwanese patients with subfoveal CNV secondary to AMD , 2012, Graefe's Archive for Clinical and Experimental Ophthalmology.

[3]  Glenn J Jaffe,et al.  Ranibizumab and bevacizumab for neovascular age-related macular degeneration. , 2011, The New England journal of medicine.

[4]  A. Tsujikawa,et al.  Factors associated with the response of age-related macular degeneration to intravitreal ranibizumab treatment. , 2011, American journal of ophthalmology.

[5]  P. Abraham,et al.  Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2. , 2010, American journal of ophthalmology.

[6]  Y. Tano,et al.  EXTEND‐I: safety and efficacy of ranibizumab in Japanese patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration , 2010, Acta ophthalmologica.

[7]  U. Schmidt-Erfurth.  Clinical safety of ranibizumab in age-related macular degeneration , 2010, Expert opinion on drug safety.

[8]  T. Ianchulev,et al.  A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. , 2009, Ophthalmology.

[9]  J. Fernando Arevalo,et al.  Retinal Angiography and Optical Coherence Tomography , 2008 .

[10]  B. Takahashi,et al.  Verteporfin photodynamic therapy in the age of antiangiogenic therapy , 2008 .

[11]  C. Regillo,et al.  Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. , 2008, American journal of ophthalmology.

[12]  Gerald Liew,et al.  Ranibizumab for neovascular age-related macular degeneration. , 2007, The New England journal of medicine.

[13]  Claudio Campa,et al.  Targeting VEGF-A to treat cancer and age-related macular degeneration. , 2007, Annual review of medicine.

[14]  Clare Bradley,et al.  Health and Quality of Life Outcomes Quality of Life in Age-related Macular Degeneration: a Review of the Literature , 2022 .

[15]  Susan Schneider,et al.  Ranibizumab versus verteporfin for neovascular age-related macular degeneration. , 2006, The New England journal of medicine.

[16]  L. Damico,et al.  DEVELOPMENT OF RANIBIZUMAB, AN ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR ANTIGEN BINDING FRAGMENT, AS THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION , 2006, Retina.

[17]  T. Wong,et al.  The epidemiology of age related eye diseases in Asia , 2006, British Journal of Ophthalmology.

[18]  R. Klein,et al.  Prevalence of age-related macular degeneration in 4 racial/ethnic groups in the multi-ethnic study of atherosclerosis. , 2006, Ophthalmology.

[19]  S. Resnikoff,et al.  Global data on visual impairment in the year 2002. , 2004, Bulletin of the World Health Organization.

[20]  N. Bressler,et al.  The use of fundus photographs and fluorescein angiograms in the identification and treatment of choroidal neovascularization in the Macular Photocoagulation Study. The Macular Photocoagulation Study Group. , 1989, Ophthalmology.

[21]  F L Ferris,et al.  Standardized illumination for visual acuity testing in clinical research. , 1982, American journal of ophthalmology.

[22]  F. Ferris,et al.  New visual acuity charts for clinical research. , 1982, American journal of ophthalmology.

[23]  J. F. Arevalo,et al.  Clinical Applications of Optical Coherence Tomography in Age-Related Macular Degeneration , 2009 .

[24]  Mark Michels,et al.  Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. , 2009, Ophthalmology.

[25]  J. Vander,et al.  Ranibizumab for Predominantly Classic Neovascular Age-related Macular Degeneration: Subgroup Analysis of First-year ANCHOR Results , 2008 .

[26]  Ching-Yu Cheng,et al.  Prevalence and causes of visual impairment in an elderly Chinese population in Taiwan: the Shihpai Eye Study. , 2004, Ophthalmology.

[27]  F L Ferris,et al.  Standardizing the measurement of visual acuity for clinical research studies: Guidelines from the Eye Care Technology Forum. , 1996, Ophthalmology.